45 related articles for article (PubMed ID: 15056224)
21. Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer.
Davies EJ; Blackhall FH; Shanks JH; David G; McGown AT; Swindell R; Slade RJ; Martin-Hirsch P; Gallagher JT; Jayson GC
Clin Cancer Res; 2004 Aug; 10(15):5178-86. PubMed ID: 15297422
[TBL] [Abstract][Full Text] [Related]
22. Tissue microarray analysis reveals prognostic significance of syndecan-1 expression in prostate cancer.
Zellweger T; Ninck C; Mirlacher M; Annefeld M; Glass AG; Gasser TC; Mihatsch MJ; Gelmann EP; Bubendorf L
Prostate; 2003 Apr; 55(1):20-9. PubMed ID: 12640657
[TBL] [Abstract][Full Text] [Related]
23. Syndecan-1 expression in locally invasive and metastatic prostate cancer.
Chen D; Adenekan B; Chen L; Vaughan ED; Gerald W; Feng Z; Knudsen BS
Urology; 2004 Feb; 63(2):402-7. PubMed ID: 14972511
[TBL] [Abstract][Full Text] [Related]
24. Induced expression of syndecan-1 in the stroma of head and neck squamous cell carcinoma.
Mukunyadzi P; Liu K; Hanna EY; Suen JY; Fan CY
Mod Pathol; 2003 Aug; 16(8):796-801. PubMed ID: 12920224
[TBL] [Abstract][Full Text] [Related]
25. Clinicopathological study of the expression of syndecan-1 in invasive breast carcinomas. correlation with extracellular matrix components.
Tsanou E; Ioachim E; Briasoulis E; Charchanti A; Damala K; Karavasilis V; Pavlidis N; Agnantis NJ
J Exp Clin Cancer Res; 2004 Dec; 23(4):641-50. PubMed ID: 15743035
[TBL] [Abstract][Full Text] [Related]
26. Altered expression of syndecan-1 in prostate cancer.
Kiviniemi J; Kallajoki M; Kujala I; Matikainen MT; Alanen K; Jalkanen M; Salmivirta M
APMIS; 2004 Feb; 112(2):89-97. PubMed ID: 15056224
[TBL] [Abstract][Full Text] [Related]
27. [Proteoglycans in the liver].
Kovalszky I; Dudás J; Gallai M; Hollósi P; Tátrai P; Tátrai E; Schaff Z
Magy Onkol; 2004; 48(3):207-13. PubMed ID: 15520870
[TBL] [Abstract][Full Text] [Related]
28. [Syndecans in the diagnosis and prognosis of prostate cancer].
Contreras HR
Rev Med Chil; 2010 Jan; 138(1):95-101. PubMed ID: 20361158
[TBL] [Abstract][Full Text] [Related]
29. Heparanase-2 and syndecan-1 in colon cancer: the ugly ducklings or the beautiful swans?
Giordano RJ
Eur J Gastroenterol Hepatol; 2008 Aug; 20(8):716-8. PubMed ID: 18528290
[TBL] [Abstract][Full Text] [Related]
30. Targeting syndecans: a promising strategy for the treatment of cancer.
Choi S; Kang DH; Oh ES
Expert Opin Ther Targets; 2013 Jun; 17(6):695-705. PubMed ID: 23421390
[TBL] [Abstract][Full Text] [Related]
31. Role of Syndecans in Ovarian Cancer: New Diagnostic and Prognostic Biomarkers and Potential Therapeutic Targets.
Oto J; Le QK; Schäfer SD; Kiesel L; Marí-Alexandre J; Gilabert-Estellés J; Medina P; Götte M
Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370735
[TBL] [Abstract][Full Text] [Related]
32. Syndecan-1 (CD138) as a Pathogenesis Factor and Therapeutic Target in Breast Cancer.
Sheta M; Götte M
Curr Med Chem; 2021; 28(25):5066-5083. PubMed ID: 34191695
[TBL] [Abstract][Full Text] [Related]
33. Syndecans in cancer: A review of function, expression, prognostic value, and therapeutic significance.
Czarnowski D
Cancer Treat Res Commun; 2021; 27():100312. PubMed ID: 33485180
[TBL] [Abstract][Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
